Skip to main content
. 2012 Jun 1;86(6):959–961. doi: 10.4269/ajtmh.2012.11-0467

Table 3.

Drug use and PKDL presentation in VL-treated cases, Bihar, India

Anti-leishmanial drug No. (%) patients Median time lapse after treatment (months) Range (months)
Sodium antimony gluconate 62 (72.9) 23 1–192
Amphotericin B 13 (15.3) 29 8–106
AmBisome 2 (2.4) 9 5–13
Miltefosine 4 (4.7) 31 29–42
Paramomycin 4 (4.7) 25 19–37

PDKL = post–kala-azar dermal leishmaniasis; VL = visceral leishmaniasis.